ECO Animal Health Group plc (EAH.L)
ValueMarkers Composite Index
45% below intrinsic value ($2)
ECO Animal Health Group plc (EAH.L) — VMCI valuation read
EAH.L prints VMCI 55/100 inside the Healthcare sector, where the median sits at 50. The 5-point above-median delta is the cleanest single-number summary of ECO Animal Health Group plc's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.
On EAH.L, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** EAH.L trades at 26.0x earnings, 44% above the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of -2.0x leaves covenant headroom; that is the risk line for ECO Animal Health Group plc on the trailing financials.
EAH.L fell 1.4% over the trailing 7 days, with a +7.6% read on a 30-day basis.
ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. ECO Animal Health Group plc was founded in 1972 and is headquartered in New Malden, the United Kingdom.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.